212 related articles for article (PubMed ID: 33593826)
1. Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model.
Wen J; Wang L; Ren J; Kranz E; Chen S; Wu D; Kanazawa T; Chen I; Lu Y; Kamata M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593826
[TBL] [Abstract][Full Text] [Related]
2. A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo.
Verma MK; Clemens J; Burzenski L; Sampson SB; Brehm MA; Greiner DL; Shultz LD
J Immunol Methods; 2017 Jul; 446():47-53. PubMed ID: 28390927
[TBL] [Abstract][Full Text] [Related]
3. Anti-human SIRPα antibody is a new tool for cancer immunotherapy.
Murata Y; Tanaka D; Hazama D; Yanagita T; Saito Y; Kotani T; Oldenborg PA; Matozaki T
Cancer Sci; 2018 May; 109(5):1300-1308. PubMed ID: 29473266
[TBL] [Abstract][Full Text] [Related]
4. A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model.
Sato F; Ito A; Ishida T; Mori F; Takino H; Inagaki A; Ri M; Kusumoto S; Komatsu H; Iida S; Okada N; Inagaki H; Ueda R
Cancer Immunol Immunother; 2010 Dec; 59(12):1791-800. PubMed ID: 20714721
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma.
Choi B; Lee JS; Kim SJ; Hong D; Park JB; Lee KY
Cancer Lett; 2020 May; 478():56-69. PubMed ID: 32145342
[TBL] [Abstract][Full Text] [Related]
6. Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.
Patra-Kneuer M; Chang G; Xu W; Augsberger C; Grau M; Zapukhlyak M; Ilieva K; Landgraf K; Mangelberger-Eberl D; Yousefi K; Berning P; Kurz KS; Ott G; Klener P; Khandanpour C; Horna P; Schanzer J; Steidl S; Endell J; Heitmüller C; Lenz G
Front Immunol; 2023; 14():1220558. PubMed ID: 37600821
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
[TBL] [Abstract][Full Text] [Related]
8. A germline-competent embryonic stem cell line from NOD.Cg-Prkdc ( scid ) Il2rg ( tm1Wjl )/SzJ (NSG) mice.
Landel CP; Dunlap J; Patton JB; Manser T
Transgenic Res; 2013 Feb; 22(1):179-85. PubMed ID: 22767020
[TBL] [Abstract][Full Text] [Related]
9. FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion.
Oldham RJ; Mockridge CI; James S; Duriez PJ; Chan HTC; Cox KL; Pitic VA; Glennie MJ; Cragg MS
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554613
[TBL] [Abstract][Full Text] [Related]
10. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
Wang M; Yao LC; Cheng M; Cai D; Martinek J; Pan CX; Shi W; Ma AH; De Vere White RW; Airhart S; Liu ET; Banchereau J; Brehm MA; Greiner DL; Shultz LD; Palucka K; Keck JG
FASEB J; 2018 Mar; 32(3):1537-1549. PubMed ID: 29146734
[TBL] [Abstract][Full Text] [Related]
11. Outbreak of Opportunistic Ascending Pyelonephritis with Numerous Yeast after Experimental Humanization Surgery in NOD.Cg-
Zadrozny LM; Brinster LR; Rosenzweig BA; Howard KE
Comp Med; 2018 Oct; 68(5):353-359. PubMed ID: 30208988
[TBL] [Abstract][Full Text] [Related]
12. Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma.
Chu Y; Nayyar G; Kham Su N; Rosenblum JM; Soon-Shiong P; Lee J; Safrit JT; Barth M; Lee D; Cairo MS
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33109629
[TBL] [Abstract][Full Text] [Related]
13. Development of Teratocarcinomas and Teratomas in Severely Immunodeficient NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl)/Szj (NSG) Mice.
Lim CY; Solter D; Knowles BB; Damjanov I
Stem Cells Dev; 2015 Jul; 24(13):1515-20. PubMed ID: 25897827
[TBL] [Abstract][Full Text] [Related]
14. Degenerative Myelopathy and Neuropathy in NOD.
Yang P; Freeman ZT; Dysko RC; Hoenerhoff MJ
Toxicol Pathol; 2022 Apr; 50(3):390-396. PubMed ID: 35450478
[TBL] [Abstract][Full Text] [Related]
15. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
17. Morphologic and Immunohistochemical Characterization of Spontaneous Lymphoma/Leukemia in NSG Mice.
Tillman H; Janke LJ; Funk A; Vogel P; Rehg JE
Vet Pathol; 2020 Jan; 57(1):160-171. PubMed ID: 31736441
[TBL] [Abstract][Full Text] [Related]
18. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
Li B; Shi S; Qian W; Zhao L; Zhang D; Hou S; Zheng L; Dai J; Zhao J; Wang H; Guo Y
Cancer Res; 2008 Apr; 68(7):2400-8. PubMed ID: 18381448
[TBL] [Abstract][Full Text] [Related]
19. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101.
Dalle S; Reslan L; Besseyre de Horts T; Herveau S; Herting F; Plesa A; Friess T; Umana P; Klein C; Dumontet C
Mol Cancer Ther; 2011 Jan; 10(1):178-85. PubMed ID: 21220500
[TBL] [Abstract][Full Text] [Related]
20.
St Jean SC; Ricart Arbona RJ; Mishkin N; Monette S; Wipf JRK; Henderson KS; Cheleuitte-Nieves C; Lipman NS; Carrasco SE
Vet Pathol; 2024 Jan; 61(1):145-156. PubMed ID: 37434451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]